TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04790253

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic cranial irradiation
Description: Prophylactic cranial irradiation (PCI) is a technique used to combat the occurrence of metastasis to the brain in highly aggressive cancers that commonly metastasize to brain, most notably small-cell lung cancer.
Study: NCT05036642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compliant Passive Arm Support
Description: The device is a mechanical device that consists of two linkages, elastic bands, a commercial posture brace, and a hook-and-loop fastener. The design of the device, with several compliant elements, ensures that one device fits many without joint alignment concerns. No motors or other actuators add energy into the system, meaning that it is stable.
Study: NCT06065163

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diuretic de/escalation based on clinical findings (CCS Score)
Description: Patients allocated in the experimental arm will have diuretic dosing adjusted based on clinical findings (CCS Score)
Study: NCT04872686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient
Description: Number of participants 768 COVID-19 positive, moderately ill admitted patient who will receive intervention~Step 1: Enrollment of the study populations by applying inclusion and exclusion criteria Step 2: Randomization to allocate experimental and controlled group by using table of random number Step 3: Application of 0.6% PVP-I spray to experimental group and distilled water to control group Step 4: Follow up (waiting for 2-5 minutes) Step 5: Collection of nasopharyngeal and oropharyngealsawab for RT-PCR test for both group Step 6: Observation of the patients for 30 minutes for possible early adverse effects (if any) and subsequent management (if needed).~Step 7: Analysis data collection, data processing and analysis by using SPSS software.
Study: NCT05365022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROSA® System Robotic Assisted Knee Prosthetic Surgery
Description: Robotic Assisted Knee Prosthetic Surgery using ROSA® (Zimmer-Biomet) System
Study: NCT05775536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 500Mg Tab
Description: Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dr. Böhm® Omega 3 complex 870 mg
Description: Dose: 2 tablets per day starting from visit 2 until visit 3, intake in the evening
Study: NCT06248073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: on-line self-management training
Description: To encourage adherence to the home program among early-stage Parkinson's disease participants, the investigators have developed various self-management topics, including medication adherence and exercise benefits. The home program is categorized into two dimensions: daily function and exercise. The investigators will provides participants with detailed guidelines to ensure safe execution of the program independently.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: onsite task-related training
Description: Participants will receive interventions at Chang Gung Memorial Hospital. A certified occupational therapist will conduct the interventions. These sessions will involve functional tasks tailored to each participant's skill level, with two to four varied tasks per session. Additionally, participants will be given booklets to guide them in self-managing similar exercises at home, mirroring the home program of the self-management group.
Study: NCT04675528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP107(Oral paclitaxel)
Description: DHP107 200 mg/m\^2 orally twice daily on Day 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m\^2 orally once daily on Day 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP107(Oral paclitaxel)
Description: DHP107 200 mg/m\^2 orally twice daily on Day 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m\^2 orally once daily on Day 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)
Study: NCT06682949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: Participants, their parent, and a researcher will review the participants actigraphy data from the two week baseline period. They will discuss sleep patterns and behaviors related to sleep. The researcher will prescribe a sleep prescription that includes set sleep and wake times and stimulus control. Participants will adhere to the sleep prescription for two weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daytime Routine
Description: Participant, their parent, and researcher will meet to discuss daily routines for the child and family. They will collaborate to choose one behavioral routine to modify for the following two weeks.
Study: NCT06696534

Intervention type: OTHER
Group type: OTHER
Intervention: Survey using a questionnaire.
Description: Preference questionnaire for colorectal cancer screening methods

Intervention type: OTHER
Group type: OTHER
Intervention: Survey using a questionnaire.
Description: Experience questionnaire into colorectal cancer screening programme
Study: NCT06700590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Treatment
Description: Participants engage in two preparatory sessions once weekly, lasting 50 minutes each, which focus on psychoeducation and case conceptualization. The core treatment consists of five days of twice-daily sessions delivered over one or two weeks. The first session of the day consists of prolonged exposure (PE). The second session consists of eye movement desensitization and reprocessing (EMDR). Both treatments are performed in strict adherence to their respective manualized protocol. Two closing sessions focus on lessons learned, integration and a prevention plan. The treatment in total lasts 6 weeks and contains 800 minutes of treatment.~To enhance practicality, treatment rotation is allowed and encouraged. Rigorous checks on treatment adhenrence will be implemented.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Spaced/weekly treatment consists of a treatment-as-usual condition, increasing the representativeness of the control condition. Treatment duration is 800 minutes, either 13 weeks of 60 minutes (with the last sessions being 80 minutes), or 16 weeks of 50 minutes. All evidence-based treatment modalities of the Dutch guidelines are allowed: PE, EMDR, brief eclectic psychotherapy for PTSD (BEPP), narrative exposure therapy (NET), and imaginary rescripting (ImRs). All have common elements of psychoeducation, imaginal exposure, emotional processing, cognitive restructuring and/or meaning making. Treatment adherence will be monitored throughout the intervention. Therapist rotation is not performed
Study: NCT06702176

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT active
Description: Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more. EXOPULSE Mollii suit consists of transcutaneous stimulation of several muscles by means of a feeble electric current (i.e., low frequency \~20 Hz, low-intensity 2mA), aiming to reduce pain. This treatment method theoretical background primarily refers to the theory of gate control. Based on this theory, the stimulation of large proprioceptive fibers would inhibit the nociceptive information transmitted by small fibers.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT (sham)
Description: It consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 175 µs) but for a shorter duration of time (1 minute).
Study: NCT06701760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Lactate
Description: sodium lactate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: infusion of sodium chloride
Study: NCT06701968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Nordic Diet
Description: Oral and written dietary advice during the course of the interventiuon period of 18months. Participants will also receive some key food items representative for a Healthy nordic diet, e.g. whole grain rye and oats and rapeseed oil. Overall the diet is a high-fibre, moderate low-fat diet with moderate to high amounts of high-quality carbohydrates and unsaturated fats, low-fat fermented dairy products. Overall the diet is high in local fruits, legumes and vegetables and is to a large extent plant-based.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Nordic Diet
Description: Oral and written dietary advice during the course of the interventiuon period of 18months. Participants will also receive some key food items representative for a Healthy nordic diet, e.g. whole grain rye and oats and rapeseed oil. Overall the diet is a high-fibre, moderate low-fat diet with moderate to high amounts of high-quality carbohydrates and unsaturated fats, low-fat fermented dairy products. Overall the diet is high in local fruits, legumes and vegetables and is to a large extent plant-based.
Study: NCT06701110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [U-14C] WX-081
Description: A single oral dose of approximately 450 mg (100 μCi) of \[U-14C\] WX-081 will be administered to healthy male volunteers. The study will involve pharmacokinetic assessments, including metabolism, mass balance, and excretion pathways, through the collection of biological samples such as blood, plasma, urine, and feces.
Study: NCT05523310

Intervention type: OTHER
Intervention: Daily questionnaire
Description: All patients will be asked to complete a daily questionnaire regarding their migraine, medications, and prodromal symptoms during that day

Intervention type: OTHER
Intervention: Daily questionnaire
Description: All patients will be asked to complete a daily questionnaire regarding their migraine, medications, and prodromal symptoms during that day
Study: NCT06703268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 10 mg
Description: HSK7653 10 mg Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily DPP-4 inhibitor
Description: Daily DPP-4 inhibitor
Study: NCT06703931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measures performed on all subjects
Description: In intensive care Medics will use a reference medical device and Thermodiag®. Simultaneous and synchronised measurements will be taken every minute.
Study: NCT06702969

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra oral scanner
Description: Immediate implant placement with customized healing abutment and after three months placement all ceramic crown by digital impression using intra oral scanner

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: impression analog
Description: Immediate implant placement with customized healing abutment and after three months placement of all ceramic crowns by conventional impression
Study: NCT06702878

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: nasal antimicrobial photodisinfection therapy
Description: Application of NF-031 solution (methylene blue 0.01% USP (methylthioninium chloride) and 0.25% chlorhexidine gluconate) in the nares followed by 2-minutes of light with nasal illuminators. The application is repeated a second time for total treatment time of 5-minutes.
Study: NCT06703632

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sampling
Description: PreveCol test based on blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Survey using a questionnaire.
Description: Preference questionnaire for colorectal cancer screening methods

Intervention type: OTHER
Group type: OTHER
Intervention: Survey using a questionnaire.
Description: PREMs for colorectal cancer screening programme
Study: NCT06703970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: 5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Joint Injection
Description: \~3 milliliters (mL) injection of autologous PRP Magellan Autologous Concentration System, ISTO Biologics
Study: NCT06703749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with BTL-899M
Description: The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. Each therapy session will last 30 minutes. The starting intensity of the radiofrequency energy will be set to 100%. The intensities of both energies will be adjusted according to the patient's feedback.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Treatment with BTL-899M with intensities below therapeutic threshold
Description: The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. Each therapy session will last 30 minutes. The intensities of both energies will be set below the therapeutic threshold.
Study: NCT06704074

Intervention type: DEVICE
Group type: OTHER
Intervention: virtual reality (VR) head mounted display
Description: The participants' in this group were given VR-TOT training under real home scenes created in the platform of Unity. There were 6 VR-TOT tasks, and the task choice was according to the performance of participants' upper limb function. The experienced therapist will guide and monitor the participants and adjust the task if necessary.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality (VR) head mounted display
Description: The participants' in this group were given VR-TOT training under real home scenes created in the platform of Unity. There were 6 VR-TOT tasks, and the task choice was according to the performance of participants' upper limb function. The experienced therapist will guide and monitor the participants and adjust the task if necessary.
Study: NCT06704126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive movement
Description: This study will use a passive movement protocol delivered on a Biodex isokinetic dynamometer at 1Hz for 60 seconds on, 60 seconds off, for a total of 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive movement with blood flow restriction
Description: This study will use a passive movement protocol delivered on a Biodex isokinetic dynamometer at 1Hz for 60 seconds on, 60 seconds off, for a total of 30 minutes. During the 60 seconds on of passive movement training, blood flow restriction cuffs which will be applied to the legs, will be inflated to cause 80% arterial blood flow occlusion.
Study: NCT06702813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency Oscillatory Ventilation
Description: Administer 10 minutes of high-frequency oscillatory ventilation in awake ICU patients.
Study: NCT06453720

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: A colonoscopy will be performed as part of routine clinical care for all participants, with the study not requiring any additional scheduling commitments outside of routine care.

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: A colonoscopy will be performed as part of routine clinical care for all participants, with the study not requiring any additional scheduling commitments outside of routine care.
Study: NCT06463756

Intervention type: OTHER
Intervention: AI
Description: Radiomics extracts quantitative information from medical images to generate high-dimensional feature vectors for analysis. It aims to provide insights into disease processes and improve diagnosis.~Deep learning utilizes neural networks with multiple layers to learn complex patterns from data. In medical imaging, it enables accurate and efficient analysis for disease detection and diagnosis.

Intervention type: OTHER
Intervention: AI
Description: Radiomics extracts quantitative information from medical images to generate high-dimensional feature vectors for analysis. It aims to provide insights into disease processes and improve diagnosis.~Deep learning utilizes neural networks with multiple layers to learn complex patterns from data. In medical imaging, it enables accurate and efficient analysis for disease detection and diagnosis.

Intervention type: OTHER
Intervention: AI
Description: Radiomics extracts quantitative information from medical images to generate high-dimensional feature vectors for analysis. It aims to provide insights into disease processes and improve diagnosis.~Deep learning utilizes neural networks with multiple layers to learn complex patterns from data. In medical imaging, it enables accurate and efficient analysis for disease detection and diagnosis.
Study: NCT06316960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: 50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd, d1-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: 75mg/m2/d for weighing \>10kg, 2.5mg/kg/d for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine Injection
Description: 20mg/m2/d for weighing \>10kg, 0.67mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin Hydrochloride
Description: 5mg/m2/day for weighing \>10kg, 0.17mg/kg/day for weighing ≤ 10kg, d 6, 8, 10 (d 8, 10, 12 for azacitidine) ivgtt, qod, more than 1 hour at 10 am.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 10mg/m2/day for weighing \>10kg, 0.33mg/kg/day for weighing ≤ 10kg, d6-15 （d8-17 for azacitidine ）, s.c., q12h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: 300ug/day for weighing \>10kg, 10ug/kg/day for weighing ≤10kg, d0-5, s.c., qd.
Study: NCT06204536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tech-enabled ABA treatment planning
Description: The tech-enabled ABA treatment planning will involve the use of a proprietary MLA integrated within a proprietary software application for use on a tablet, phone, or other smart device by BCBAs (one proprietary software application, one non-proprietary software application). The proprietary application provides functionality for treatment plan development, including templates and centralized resource availability. This tech will be used as adjunct or auxiliary tools to develop and manage ABA treatment plans. The proposed period of time for this intervention (the latter portion of the study subsequent to the non-interventional phases) will be 24 months.
Study: NCT06297941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REM-422
Description: REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~REM-422 will be administered orally once daily
Study: NCT05358392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emotional freedom technique (EFT)
Description: EFT is an energy psychotherapy derivative application, consisting of cognitive and somatic components, used to heal personal negative emotions and related emotional and physical disorders. Stress hormones are secreted in response to the stress response in the person, and then the amygdala and other cerebral parts that respond to stress are activated. There are basic steps to be followed in EFT application; By giving a message to the emotional body (subconscious) with suggestion sentences, clicks are made on the twelve energy meridian endpoints (acupressure points).
Study: NCT05957913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada (tenofovir/emtricitabine)
Description: Doses and route of administration of the study drug will be kept the same as for the FDA-approved indication of HIV-1 prevention in healthy individuals. The study drug is not FDA-approved for the treatment of multiple sclerosis.
Study: NCT05623449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: Current medications (only those prescribed to treat pain, anxiety and depression), non-drug treatment(s) prior to treatment in hypnosis as well as any ongoing treatment(s).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical examination
Description: Current medications (only those prescribed to treat pain, anxiety and depression), non-drug treatment(s) prior to treatment in hypnosis as well as any ongoing treatment(s).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety and Depression Scale (HAD)
Description: To screen for anxious and depressive symptoms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anxiety and Depression Scale (HAD)
Description: To screen for anxious and depressive symptoms

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain scale
Description: Measurement of pain intensity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pain scale
Description: Measurement of pain intensity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypnosis consultation
Description: 5 hypnosis consultation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hypnosis consultation
Description: 5 hypnosis consultation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maintenance
Description: Qualitative assessment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance
Description: Qualitative assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data collection
Description: Age, sex, socio-professional category, level of education, comorbidities, date of diagnosis of chronic peripheral neuropathic pain, distance between home and hospital.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data collection
Description: Age, sex, socio-professional category, level of education, comorbidities, date of diagnosis of chronic peripheral neuropathic pain, distance between home and hospital.
Study: NCT06180577

Intervention type: DEVICE
Intervention: Nerivio
Description: Nerivio is a prescribed Remote Electrical Neuromodulation (REN) device for treatment of migraine